Common Carotid Intima-Media Thickness Relates to Cardiovascular Events in Adults Aged < 45 Years by Eikendal, ALM et al.
ONLINE SUPPLEMENT 
Common carotid intima-media thickness relates to cardiovascular events in 
adults under the age of 45 years  
Anouk L.M. Eikendal 1, Karlijn A. Groenewegen 2, Todd J. Anderson 3, Annie R. 
Britton 4, Gunnar Engström 5, Greg W. Evans 6, Jacqueline de Graaf 7, Diederick E. 
Grobbee 2,8, Bo Hedblad 9, Suzanne Holewijn 10, Ai Ikeda 11, Kazuo Kitagawa 12, 
Akihiko Kitamura 11, Eva M. Lonn 13, Matthias W. Lorenz 14, Ellisiv B. Mathiesen 15, 
Giel Nijpels 16, Jacqueline M. Dekker 16, Shuhei Okazaki 17, Daniel H. O’Leary 18, 
Joseph F. Polak 18, Jacqueline F. Price 19, Christine Robertson 19, Christopher M. 
Rembold 20, Maria Rosvall 9, Tatjana Rundek 21, Jukka T. Salonen 22, Matthias Sitzer 
23, Coen D.A. Stehouwer 24, Imo E. Hoefer25, Sanne A.E. Peters 2,26, Michiel L. Bots 2, 
Hester M. den Ruijter 2,25 on behalf of the USEIMT Project Group S3 
1. Department of Radiology, University Medical Center, Utrecht, the Netherlands; 2. 
Julius Center for Health Sciences and Primary Care , University Medical Center, 
Utrecht, the Netherlands; 3. Department of Cardiac Sciences and Libin 
Cardiovascular Institute of Alberta, University of Calgary, Alberta, Canada; 4. 
Department of Epidemiology and Public Health University College London, London, 
United Kingdom; 5. Department of Clinical Sciences in Malmö”, Lund University, 
Skåne University Hospital, Malmö, Sweden; 6. Department of Biostatistical Sciences 
and Neurology, Wake Forest School of Medicine, Winston-Salem, NC, United States 
of America; 7. Department of General Internal Medicine, Division of Vascular 
Medicine, Radboud University Medical Centre Nijmegen, The Netherlands; 8. 
University of Malaya Medical Center, Kuala Lumpur, Malaysia; 9. Department of 
Clinical Sciences in Malmö, Lund University, Skåne University Hospital, Malmö, 
Sweden; 10. Department of General Internal Medicine, Division of Vascular Medicine, 
Radboud University Medical Centre, Nijmegen, The Netherlands; 11. Osaka Medical 
Center for Health Science and Promotion, Osaka, Japan; 12. Department of 
Neurology, Tokyo Women Medical University, Tokyo, Japan; 13. Department of 
Medicine, Division of Cardiology and Population Health Research Institute, McMaster 
University, Hamilton, Ontario, Canada; 14. Department of Neurology, University 
Hospital, Goethe-University, Frankfurt am Main, Germany; 15. Brain and Circulation 
Research Group, Department of Clinical Medicine, University of Tromsø, Tromsø, 
Norway; 16. Institute for Health and Care Research, VU University Medical Center, 
Amsterdam, The Netherlands; 17. Stroke Center, Department of Neurology, Osaka 
University Graduate School of Medicine, Osaka, Japan; 18. Department of Radiology, 
Tufts Medical Center, Boston, MA, United States of America; 19. Centre for 
Population Health Sciences, University of Edinburgh, United Kingdom; 20. 
Cardiology Division, Department of Internal Medicine, University of Virginia, 
Charlottesville, VA, United States of America; 21. Department of Neurology, Miller 
School of Medicine, University of Miami, Miami, Fl, United States of America; 22. 
MAS-Metabolic Analytical Services Oy; 23. Department of Neurology, University 
Hospital, Goethe-University, Frankfurt am Main, Germany and Department of 
Neurology Klinikum Herford, Germany; 24. Department of Internal Medicine and 
Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, 
Maastricht, The Netherlands; 25. Department of Experimental Cardiology, University 
Medical Center Utrecht, the Netherlands; 26. The George Institute for Global Health, 
Nuffield Department of Population Health, University of Oxford, Oxford, United 
Kingdom. 
Short  title: CIMT and cardiovascular events in the young  
Word count:  5630 
Corresponding author:  
Anouk L.M. Eikendal, MD 
Department of Radiology (HP: E.01.132) 
University Medical Center 
Heidelberglaan 100, 3584 CX Utrecht 
P.O. Box 85500 
The Netherlands 
e-mail: a.l.m.eikendal@umcutrecht.nl 
phone/fax: +310621978619/+310302581098 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental methods 
Statement of Medical Ethical Committee of UMC Utrecht regarding the Non-
Medical Research Involving Human Subjects Act complicity of the current 
study 
 
  
 
5 
 
Supplemental references 
 
1. den Ruijter HM, Peters SA, Groenewegen KA et al. Common carotid intima-media thickness does not add to Framingham 
risk score in individuals with diabetes mellitus: The USE-IMT initiative. Diabetologia. 2013;56:1494-1502. 
2. Den Ruijter HM, Peters SA, Anderson TJ et al. Common carotid intima-media thickness measurements in cardiovascular risk 
prediction: A meta-analysis. JAMA : the Journal of the American Medical Association. 2012;308:796-803. 
3. Lorenz MW, Schaefer C, Steinmetz H, Sitzer M. Is carotid intima media thickness useful for individual prediction of 
cardiovascular risk? Ten-year results from the Carotid Atherosclerosis Progression Study (CAPS). European Heart Journal. 
2010;31:2041-2048. 
4. Anderson TJ, Charbonneau F, Title LM, Buithieu J, Rose MS, Conradson H, Hildebrand K, Fung M, Verma S, Lonn EM. 
Microvascular function predicts cardiovascular events in primary prevention: Long-term results from the Firefighters And 
Their Endothelium (FATE) study. Circulation. 2011;123:163-169. 
5. Salonen R, Salonen JT. Determinants of carotid intima-media thickness: A population-based ultrasonography study in 
eastern Finnish men. Journal of Internal Medicine. 1991;229:225-231. 
6. Kitagawa K, Hougaku H, Yamagami H et al. Carotid intima-media thickness and risk of cardiovascular events in high-risk 
patients. Results of the Osaka follow-up study for carotid atherosclerosis 2 (OSACA2 study). Cerebrovasc Dis. 2007;24:35-
42. 
7. Stensland-Bugge E, Bonaa KH, Joakimsen O, Njolstad I. Sex differences in the relationship of risk factors to subclinical 
carotid atherosclerosis measured 15 years later : The Tromsø study. Stroke; a journal of cerebral circulation. 2000;31:574-
581. 
8. Ali YS, Rembold KE, Weaver B, Wills MB, Tatar S, Ayers CR, Rembold CM. Prediction of major adverse cardiovascular 
events by age-normalized carotid intimal medial thickness. Atherosclerosis. 2006;187:186-190. 
9. Myocardial infarction redefined: A consensus document of the Joint European Society of Cardiology/American College of 
Cardiology Committee for the Redefinition of Myocardial Infarction. European Heart Journal. 2000;21:1502-1513. 
 
 
 
 
 
 
 
 
 
6 
 
Supplemental tables 
 
Table S1. Method section of each cohort1, 2 
 
Study Name Study design CV risk factor 
measurement 
Event measurement CIMT measurement Reproducibility 
information 
Carotid 
Atherosclerosis 
Progression 
Study (CAPS)3 
2006, Germany 
  
Prospective 
population based 
cohort study 
(n=3889) 
Members of German 
primary healthcare 
scheme 
No event (MI or 
stroke) before 
baseline visit 
CV risk factors 
obtained using 
standardized 
computer-assisted 
interview technique, 
examination by a 
physician trained in 
vascular medicine and 
blood sampling 
Median follow up: 8.1 years (7.4, 9.1). Follow up 
time: from date of examination to date of 
endpoints: first‐ever fatal/non-fatal MI, stroke or 
date of death. Follow up also terminated when 
patients withdrew from the study or died from 
other causes. Identification of endpoints using 
ICD codes for CV events and mortality, 
questionnaires for participants and information 
obtained from their physicians. Follow-up time 
for each patient included in analyses 
P700SE, Philips. CCA (20-
60mm proximal from flow 
divider), CB, ICA (0-20mm 
distally from flow divider), 
digitally captured during 
systole. Measured offline, 
automated (Matlab.) 
Calibration measurements 
with phantom in 1 in 100 
patients 
Gain was adjusted 
so that least dense 
arterial wall 
interface was just 
visible. Inter-
observer 
reliabilities (15 
subjects): ICC 
0.97, intra-
observer: ICC 0.93 
The Firefighters 
and Their 
Endothelium 
Study (FATE)4 
2011, Canada 
 
Prospective 
population based 
cohort study 
(n=1441) 
Healthy men at 
low/intermediate 
Framingham Risk  
Free from 
symptomatic CVD at 
baseline 
CV risk factors 
obtained using a 
detailed interview and 
questionnaire and 
blood sampling. Risk 
factors defined 
according to current 
guidelines 
 
Mean follow up: 7.2 (± 1.7 years). Follow up time: 
from date of examination to date of first‐ever MI, 
stroke or date of death. Telephone follow up was 
obtained every 12 months in which next to 
information on events, also information on 
withdrawal, loss to follow up and non-end point 
deaths was documented. Endpoints: composite 
of CV death; resuscitated cardiac arrest; nonfatal 
first time MI; revascularization coronary, carotid 
or peripheral circulation; symptomatic CVD with 
>50% stenosis documented by angiography and 
documented stroke or TIA. Identification of 
endpoints: by documents on events, verified by 
local site investigator and reviewed by end-point 
committee. Follow-up time for each patient 
included in analyses 
 
Acuson/Acoustic 
Response Technology 
ART 1 imaging System. 
Right CCA, proximal to 
flow divider. Thickest 
region identified 
(circumferential scan). 
Measured manually traced 
lumen-to-intima and 
media-to-adventitia 
interfaces, using locally 
developed software 
Within-observer: 
ICC 0.89, 
between-observer: 
0.92 
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Kuopio Ischaemic 
Heart Disease 
Risk Factor Study 
(KHID)5 
1991, Finland 
Prospective 
population based 
cohort study (n=879) 
Eastern Finnish men 
aged 42,48,54, 60 
years 
Free from history of 
CVD at baseline 
CV risk factors 
obtained  using 
questionnaires and 
interviews, examination 
by a study nurse and 
blood sampling 
 
 
Median follow up: 14.2 years (13.2, 15.2).  Follow 
up time: from date of examination to date of 
endpoints: first‐ever MI, stroke or date of death. 
There were no losses to follow up. Identification 
of endpoints using hospital files, stroke registry 
and death certificate registry (1984-1992). From 
1993, computer linkage to Finnish national 
hospital discharge registry and death certificate 
registry using unique Finnish identification 
number. Endpoints were coded according to the 
ICD codes for MI and stroke and checked for first 
time MI/stroke. Follow-up time for each patient 
included in analyses 
 
ATL UM4 duplex 
ultrasound system. Right 
and left CCA and CB, max 
CIMT located. Measured 
recorded on videotape. 
Image Measure 
morphometry software 
 
Reproducibility: 50 
subjects 
rescanned by 
same scanner, 
other reader. 
Correlation: 0.91. 
Difference: mean -
0.03 mm, SD 0.09, 
range -0.17=0.16 
mm) 
Osaka Follow-Up 
Study for Carotid 
Atherosclerosis 2  
(OSACA 2)6 
2007, Japan 
 
Prospective 
population based 
cohort study (n=403) 
High risk patients ≥ 
40 years of age (>1 
CV risk factor) 
Free from history of 
CVD events, 
endartectomy or 
carotid artery stenting 
CV risk factors 
obtained using clinical 
records and self-
reports at time of 
enrollment, physical 
examination and blood 
sampling 
Median follow up 4.6 years (3.3, 6.1). Follow up 
time: from date of examination to date of first‐
ever MI, stroke or date of death. Follow up also 
terminated when patients withdrew from the study 
because of death or for personal reasons. 
Identification of endpoints: first occurrence of 
major CV event: nonfatal stroke/TIA, nonfatal 
MI, hospitalization for AP, arterial 
revascularization procedure (PCI, bypass 
graft) or confirmed death from CV causes. 
Endpoints assessed by investigators blinded 
to baseline data. Follow-up time for each 
patient included in analyses 
 
Phillips SONOS 5500 
equipped with a 3- to 11-
MHz linear-array 
transducer. CCA, CB, ICA, 
near and far wall, mean of 
max-IMT calculated. 
Measured using electronic 
caliper on frozen frame of 
longitudinal B-mode image 
In 36 patients: 
intra-observer 
correlation 0.98, 
inter-observer 
correlation for 47 
patients 0.94, 
differences in both 
cases not 
significant 
Tromsø Study7 
2000, Norway 
 
Prospective 
population based 
cohort study 
(n=4240) 
Inhabitants of 
municipality of 
Tromsø 
Baseline CV risk 
factors collected using 
self-administered 
questionnaires, 
physical examination 
and blood sampling 
Median follow up 10.7 years (10.4, 11.0). Follow 
up time: from date of screening to date of 
endpoints: first‐ever fatal/non-fatal MI, stroke or 
date of death. Follow up also terminated when 
patients withdrew from study because of 
migration or death. Identification of endpoints 
using computer linkage to national and local 
diagnosis registries (University Hospital of North 
Norway, outpatient diagnoses included) and 
National Causes of Death Registry at Statistics 
Norway using unique Norwegian identification 
number. Cases were identified according to ICD 
Acuson 128 XP/10c ART 
upgraded. Three images 
(of CCA and CB) selected 
for offline reading (with 
optimal visibility). 
Measured via offline 
reading, using automated 
software (AMS) 
No systematic 
differences 
between observers 
or within 
observers, 
however precision 
decreased with 
increasing CIMT 
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Exclusion of persons 
with previous history 
of MI or stroke 
codes for MI and stroke. Adjudication of 
endpoints by endpoint committee consisting of 
experienced physicians. Follow-up time for each 
patient included in analyses 
 
Charlottesville 
Study8 
2006, USA 
 
Prospective 
population based 
cohort study (n=610) 
Exclusion of persons 
with prior history of 
MI or stroke 
 
Assessment of 
baseline CV risk 
factors using 
questionnaires and a 
physical examination. 
Blood samples were 
obtained 
retrospectively 
Mean follow up 4.1 years (2.7, 5.0). Follow up 
time: from date of examination to date of first‐
ever fatal/non-fatal MI, stroke or date of death. 
Telephone follow up was obtained in which 
adjacent to information on events, also 
information on withdrawal and loss to follow up 
was documented . Endpoint: MACE: new MI, 
arterial revascularization, (PCI, bypass graft), or 
stroke/TIA. Identification of endpoints by 
telephone interviews with participants and 
subsequent confirmation via medical records and 
consistent with AHA/ACC diagnostic criteria 
Toshiba PLM-703AT, 
Toshiba Powervision 
6000SSA370A. Near and 
far wall CCA (5mm distal 
to bulb), near far wall bulb, 
far wall internal (5mm 
distal to bulb) end diastole, 
bilateral 
- 
Abbreviations: CV: cardiovascular; CVD: cardiovascular disease CCA: common carotid artery; ICA: internal carotid artery; CB: carotid bifurcation; CIMT:  
carotid intima-media thickness;  ICD: International Statistical Classification of Diseases and Related Health Problems; MI: myocardial infarction; TIA: transient  
ischemic attack; AP: Angina Pectoris; PCI: percutaneous intervention; ICC: intraclass correlation; SD: standard deviation; AHA/ACC American Heart  
Association/American College of Cardiology 
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Table S2. Definition of MI and stroke for each cohort 
Study Name Definition of MI 
 
Definition of stroke 
Carotid 
Atherosclerosis 
Progression 
Study (CAPS)3 
2006, Germany 
  
MI was defined according to the ICD-9 classification: 
- cardiac infarction 
- coronary artery embolism, occlusion, rupture or thrombosis 
- infarction of heart, myocardium or ventricle 
- rupture of myocardium or ventricle 
- ST elevation (STEMI) and non-ST elevation (NSTEMI) MI 
Stroke was defined according to the ICD-9 
classification: 
- (non-traumatic) subarachnoid hemorrhage 
- (non-traumatic) intracerebral hemorrhage 
- other and unspecified non-traumatic intracranial 
hemorrhage 
- occlusion and stenosis of pre-cerebral arteries 
- occlusion of cerebral arteries 
- acute, but ill-defined cerebrovascular disease 
- other and ill-defined cerebrovascular disease 
- late effects of cerebrovascular disease 
 
The Firefighters 
and Their 
Endothelium 
Study (FATE)4 
2011, Canada 
 
MI was defined according to the AHA classification9: 
- detection of typical rise and gradual fall of cardiac troponin or more rapid 
rise and fall (CK-MB) of biochemical markers of myocardial necrosis with 
at least one of the following:  
o symptoms of ischemia 
o development of pathological Q waves on the ECG 
o ECG changes indicative of ischemia (e.g. ST segment elevation 
or depression) 
o Identification of an intracoronary thrombus by angiography or 
autopsy 
All nonfatal cases were confirmed using coronary angiography 
 
Stroke was defined as the presence of typical 
neurological symptoms supported by abnormalities on 
neurovascular imaging. All cases were confirmed by a 
stroke neurologist  
 
Kuopio 
Ischaemic Heart 
Disease Risk 
Factor Study 
MI was defined according to the ICD-9 and ICD-10 classification: 
- cardiac infarction 
- coronary artery embolism, occlusion, rupture or thrombosis 
Stroke was defined as a sudden onset of focal/global 
neurological deficit that  leads to death or lasts for at 
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(KHID)5 
1991, Finland 
- infarction of heart, myocardium or ventricle 
- rupture of myocardium or ventricle 
- ST elevation (STEMI) and non-ST elevation (NSTEMI) MI 
- myocardial infarction specified as acute or with a stated duration of 4 
weeks (28 days) or less from onset 
 
least more than 24 hours and of apparent vascular 
cause 
Osaka Follow-Up 
Study for Carotid 
Atherosclerosis 2  
(OSACA 2)6 
2007, Japan 
MI was defined as a nonfatal MI or confirmed death from MI. 
2 of the following 3 criteria had to be met: 
- a significant rise in serum CK level (more than two times the upper limit of 
the normal level)  
- symptoms of chest pain or compression lasting for at least 30 minutes 
- ECG changes indicative of ischemia (ST segment elevation more than 
0.1 mV in ≥1 limb leads or in ≥2 precordial leads) 
 
Stroke was defined as a sudden onset of clinical 
symptoms suggestive for neurological impairment 
and of apparent vascular cause. All cases were 
confirmed using neurovascular imaging.  
Tromsø Study7 
2000, Norway 
 
MI was defined according to an algorithm comprising the following: 
- clinical signs (typical, atypical or ill-described) and changes on the ECG 
suggestive for MI 
- clinical signs (typical) and a significant rise in the levels of myocardial 
enzymes/troponin 
- clinical signs (atypical or ill-described) and a significant rise in the levels 
of myocardial enzymes/troponin and changes on the ECG suggestive for 
MI 
- Identification of a recent MI by autopsy 
 
 
Stroke was defined as a sudden onset of focal/global 
neurological deficit that  leads to death or lasts for at 
least more than 24 hours and of apparent vascular 
cause 
 
Charlottesville 
Study8 
2006, USA 
 
MI was defined according to the AHA classification9: 
- detection of typical rise and gradual fall of cardiac troponin or more rapid 
rise and fall (CK-MB) of biochemical markers of myocardial necrosis with 
at least one of the following:  
o symptoms of ischemia 
o development of pathological Q waves on the ECG 
o ECG changes indicative of ischemia (e.g. ST segment elevation 
or depression) 
Stroke was defined as a sudden onset of focal/global 
neurological deficit that  leads to death or lasts for at 
least more than 24 hours and of apparent vascular 
cause 
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Abbreviations: ICD: International Statistical Classification of Diseases and Related Health Problems; MI: myocardial infarction; CK-MB: Creatine Kinase MB  
ECG: Electrocardiogram; ACC/AHA: American College of Cardiology / American Heart Association 
 
Table S3. Study population characteristics using ‘adjusted common CIMT’ <50th and ≥50th  percentile  
* IQR: interquartile range, BMI: body mass index, HDL: high-density lipoprotein, CIMT: carotid intima-media thickness, MI:  
myocardial infarction 
† Defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥ 90 mmHg and/or use of antihypertensive 
medication  
‡ CIMT value adjusted for age categories, sex and study. Median <50th percentile ‘adjusted’ CIMT = 0.6 mm, median ≥ 50th 
percentile ‘adjusted’ CIMT = 0.7 mm 
§ p<0.2 
|| p value of model
o identification of an intracoronary thrombus by angiography or 
autopsy 
Characteristic ‘Adjusted’ mean 
common CIMT< 50th 
percentile‡ 
(n = 1465) 
‘Adjusted’ mean common  
CIMT ≥ 50th percentile‡ 
(n = 1602) 
P value|| 
Age (years), median (IQR)* 37 (32, 42) 37 (32, 42)  
Sex, male (%) 870 (59.4) 958 (59.8)  
BMI (kg/m2), median (IQR)* 24.7 (22.5, 27.1) 25.3 (23.2, 28.1) <0.001§ 
Systolic blood pressure (mmHg), median 
(IQR)* 
120.0 (112.0, 129.0) 124.0 (115.0, 132.0) 
<0.001§ 
Diastolic blood pressure (mmHg), median (IQR)*        74.0 (65.0, 80.0) 75.0 (70.0, 85.0) <0.001§ 
Cigarette smoking status, yes (%) 403 (27.5) 448 (28.0) 0.80 
Total cholesterol level (mmol/L), median (IQR)* 5.2 (4.6, 5.9) 5.4 (4.7, 6.1) <0.001§ 
HDL cholesterol level (mmol/L), median (IQR)* 1.4 (1.2, 1.7) 1.4 (1.1, 1.7) <0.001§ 
Hypertension, yes (%)†  108 (7.4) 194 (12.1) <0.001§ 
Diabetes, yes (%) 5 (0.3) 15 (0.9) 0.06§ 
Use of antihypertensive medication, yes (%) 47 (3.2) 93 (5.8) <0.001§ 
Use of lipid lowering medication, yes (%) 20 (1.4) 33 (2.1) 0.61 
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Table S4. Relation between quartiles of mean common CIMT and first-time MI/stroke 
* Q: quartile, SD: standard deviation, CIMT: carotid intima-media thickness, MI: myocardial infarction 
† Values are standardized hazard ratios (HR) with 95% confidence intervals 
‡ Multivariable model is adjusted for age, sex, body mass index, smoking, diastolic blood pressure, total cholesterol level, HDL 
cholesterol level, presence of diabetes, use of antihypertensive medication, use of lipid lowering medication and for study 
 
 
 
 
 
 
 
 
 
 
 
 
 
Per quartile of CIMT 
mean common 
CIMT (mm)* 
Q1 
mean common 
CIMT (mm)* 
Q2 
mean common 
CIMT (mm)* 
Q3 
mean common 
CIMT (mm)* 
Q4 
Range of CIMT (mm) 0.285 - 0.560 0.563 - 0.624 0.625 - 0.680 0.682 - 1.175 
Person years 7330 6738 6767 6744 
Number of events (MI/stroke) 5 9 15 26 
Age and sex adjusted hazard ratio (reference: Q1)† - 1.49 (0.49, 4.50) 2.36 (0.84, 6.64) 3.29 (1.21, 8.94) 
Multivariable hazard ratio (reference: Q1)†‡ - 1.49 (0.49, 4.53) 2.22 (0.78, 6.29) 3.04 (1.11, 8.32) 
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Table S5. Relation between cardiovascular risk factors and mean common CIMT adjusted for SBP instead of DBP 
 
* SD: standard deviation, CIMT: carotid intima-media thickness, SBP: systolic blood pressure, DBP: diastolic blood pressure, BMI: 
body mass index, HDL: high density lipoprotein  
† Values are standardized beta’s with 95% confidence intervals 
‡ Adjusted for all risk factors included in the model and for study 
§ p<0.05 
|| p value of fully adjusted model 
** In this variable natural logarithmic transformation was performed 
 
 
 
 
Cardiovascular risk factors Mean common CIMT (ln(mm))*†‡** P value|| 
Age, per 1 SD increase* 0.042 (0.037, 0.048)            <0.001§ 
Sex (reference: female) 0.005 (0.001, 0.017) 0.04§ 
Smoking (reference: nonsmoker) 0.005 (-0.005, 0.016) 0.33 
SBP, per 1 SD increase* 0.015 (0.009, 0.021)            <0.001§ 
BMI, per 1 SD  increase* 0.012 (0.007, 0.018)            <0.001§ 
Total Cholesterol, per 1 SD increase* 0.009 (0.004, 0.014)            <0.001§ 
HDL-Cholesterol, per 1 SD increase*   -0.069 (-0.013, -0.001)  0.02§ 
Diabetes mellitus (reference: no diabetes) 0.048 (-0.011, 0.106) 0.11 
Antihypertensive medication use (reference: no use) 0.008 (-0.016, 0.032) 0.52 
Lipid lowering medication use (reference: no use) -0.006 (-0.048, 0.036) 0.77 
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Table S6. Relation between mean common CIMT and first-time myocardial infarction/stroke adjusted for SBP instead of DBP 
 
* SD: standard deviation, CIMT: carotid intima-media thickness, SBP: systolic blood pressure, DBP: diastolic blood pressure, BMI: 
body mass index, HDL: high density lipoprotein 
† Values are standardized hazard ratios (HR) with 95% confidence intervals 
‡ Adjusted for all risk factors included in the model and for study 
§ p<0.05 
|| p value of fully adjusted model 
  
 
 
Cardiovascular risk factors Multivariable hazard ratio (HR)†‡ P value|| 
Mean common CIMT, per 1 SD increase* 1.38 (1.09, 1.73) 0.006§ 
Age, per 1 SD increase* 1.35 (0.90, 2.03) 0.15 
Sex (reference: female) 1.34 (0.59, 3.02) 0.48 
Smoking (reference: nonsmoker) 0.91 (0.50, 1.67) 0.77 
SBP, per 1 SD increase* 1.27 (0.97, 1.67) 0.09 
BMI, per 1 SD  increase* 0.84 (0.61, 1.15) 0.28 
Total Cholesterol, per 1 SD increase* 0.96 (0.73, 1.26) 0.80 
HDL-Cholesterol, per 1 SD increase* 0.91 (0.64, 1.30) 0.60 
Diabetes mellitus (reference: no diabetes)   2.25 (0.50, 10.11) 0.29 
Antihypertensive medication use (reference: no use) 2.98 (1.34, 6.63) 0.008§ 
Lipid lowering medication use (reference: no use)   5.01 (1.38, 18.22)   0.01§ 
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